Innovative Delivery Platform PassPort Technologies offers a unique transdermal drug delivery system that enables needle-free administration of a wide range of therapeutics, including peptides, oligonucleotides, and proteins, presenting opportunities to license or integrate this platform into pharmaceutical development pipelines.

Strategic Collaborations The company's recent partnership with Arcturus Therapeutics to explore transdermal mRNA delivery highlights potential for expanding into advanced therapeutics and cutting-edge mRNA vaccine or treatment sectors.

Market Expansion Potential With a focus on repositioning existing approved drugs and developing new NCEs for alternative routes of administration, there is significant opportunity to identify clients looking to enhance drug delivery efficacy and patient compliance.

Technology Differentiation The proprietary PassPort® System's microporation technology can be integrated into pharmaceutical R&D initiatives to create competitive advantages, appealing to companies seeking innovative and pain-free drug delivery solutions.

Growth and Funding Opportunities Although current revenue is modest, the company's strong technical foundation and recent collaborations position it favorably for future funding rounds or strategic partnerships to scale its proprietary platform and capture market share.